ArticleBrain, behavior, & immunity - health2026
Plasma proteomic profile of inflammatory depressive symptoms.
Article in Brain, behavior, & immunity - health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Previous studies suggest that specific depressive symptoms such as low energy, fatigue, sleep and appetite disturbances are associated with systemic low-grade inflammation. In this study, we investigated associations between an inflammatory symptom profile of depression and proteomic markers spanning inflammatory and metabolic pathways. Methods: We analyzed 158 proteins related to inflammation and metabolism using proximity extension assay in blood samples from 165 patients with Major Depressive Disorder (MDD). Severity of inflammatory depressive symptoms was assessed using a composite score summarizing Patient Health Questionnaire-9 (PHQ-9) items related to fatigue and sleep/appetite disturbances. We used partial least squares (PLS), PLS discriminant analysis (PLS-DA) and linear regression models to identify proteins related to inflammatory depressive symptom severity. Results: Out of the 158 proteins, 14 were selected by either PLS or PLS-DA. After false discovery rate correction, proteins identified by PLS or PLS-DA that remained significantly associated with more severe inflammatory depressive symptoms included several immunometabolic biomarkers, namelyinterleukin-6 (IL-6), hepatocyte growth factor, oncostatin M, thrombospondin-4, low affinity immunoglobulin gamma Fc region receptor II-a and intercellular adhesion molecule 1. With the exception of IL-6, none of these markers showed significant associations with the remaining PHQ-9 items that were not classified as inflammatory depressive symptoms. Conclusions: These findings support the growing body of evidence linking inflammatory and metabolic protein alterations to specific depressive symptoms.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.